As would be expected, gastrointestinal events, usually mild to moderate in severity and occurring mostly during dose titration, were the most common adverse events, and occurred with similar frequency with tirzepatide (4045% in SURPASS-2) to that seen with semaglutide (41.2%)
Real-world evidence studies from the USA and Denmark showed a significant 1142% lower risk of all-cause dementia and up to 64% lower risk of AD after GLP-1RA exposure for the treatment of T2D [32, 34,35,36,37]
Orforglipron, developed by Eli Lilly, is the first non-peptide oral GLP-1 agonist, achieving up to 1.8% HbA1c reduction and 1012% body-weight loss in Phase 3 trials
The meta-analysis of these studies resulted in no significant (SMD, 0.086
After the procedure, you should expect that, over time, your face will continue to age naturally
September 36, 2025